减肥药物塞马格卢提德的新指示
1Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch : diane.aschenbrenner@gmail.com .
The American journal of nursing
|May 26, 2023
概括
减肥药物西马格卢提德 (Wegovy) 现在已被批准用于小儿肥胖治疗. 这种药物适用于12岁及以上的肥胖患者,标志着儿童体重管理的重大进展.
科学领域:
- 药理学 药理学是指药理学的学科.
- 儿科内分泌学 儿科内分泌学
- 肥胖医学 肥胖医学
背景情况:
- 儿童肥胖是一个日益严重的公共卫生问题,具有长期健康影响.
- 目前,有限的药理选择已被批准用于青少年的长期体重控制.
- 塞马格卢提德在成人肥胖试验中证明了有效性和安全性.
研究的目的:
- 评估塞马格卢提德在儿科患者体重管理中的有效性和安全性.
- 为了确定适合肥胖青少年的剂量和管理.
- 为了支持监管部门批准在儿童群体中使用西马格卢提德的新适应症.
主要方法:
- 随机,双盲,安慰剂控制的临床试验设计.
- 包括12岁及以上患有肥胖症的儿科参与者.
- 在特定的治疗期内评估身体质量指数 (BMI) 降低和安全概况.
主要成果:
- 与安慰剂相比,塞马格卢提德治疗导致BMI在统计学上显著降低.
- 接受塞马格卢提德治疗的青少年实现了更大的体重减轻和BMI百分位数的降低.
- 安全性概况与成人研究中观察到的情况一致,胃肠道副作用是最常见的.
结论:
- 塞马格卢提德是12岁及以上儿童肥胖症的有效和安全治疗选择.
- 这项批准扩大了与肥胖作斗争的青少年的治疗选择.
- 持续监测和研究是有必要的,以评估这一群体的长期结果.
相关概念视频
Glucagon-like Receptor Agonists
372
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
372
Oral Hypoglycemic Agents: Biguanides and Glitazones
241
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
241
Oral Hypoglycemic Agents: Glinides
192
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
192
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
220
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
220
Dipeptidyl Peptidase 4 Inhibitors
217
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
217
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
162
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
162


